Pharmamel Spin-Off biotech R&D&I biotech spin-off from the University of Granada, which holds the technology license from the Andalusian Health Service and the University of Granada for an intravenous melatonin injectable to treat sepsis (the leading cause of hospital death in the world) After conducting two Phase II clinical trials and successfully demonstrating the safety and efficacy of the drug, the company has the perfect drug candidate
Company Details
- Employees
- 17
- Founded
- -
- Address
- 18009, C/ Ganivet 6,oficina 20-21. Cp. 18009 Granada,spain
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- pharmamel.com
- HQ
- Granada, Granada
Pharmamel Drug Discovery Questions
Pharmamel Drug Discovery's website is pharmamel.com
Pharmamel Drug Discovery's LinkedIn profile is https://es.linkedin.com/company/pharmameldrugdiscovery
Pharmamel Drug Discovery has
17 employees.
View email and phone details for 17
employees at Pharmamel Drug Discovery.
Pharmamel Drug Discovery's industry is
Pharmaceutical Manufacturing
Pharmamel Drug Discovery's top competitors are
Grupo Jumadi,
Fundacion Medina,
Cobiomic Bioscience Sl,
Vaxdyn,
Aridos Internacionales Del Mediterráneo S.l.,
Lentistem Biotech S.l.,
Vircell S.l.,
Capital Cell,
Plusvitech,
Inves Biofarm.
Pharmamel Drug Discovery's categories are Pharmaceutical Manufacturing
Pharmamel Drug Discovery's founding year is 2014
